SIGA TECHNOLOGIES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.755 USD | +4.09% |
|
-26.34% | +37.59% |
| May. 07 | Earnings Flash (SIGA) SIGA TECHNOLOGIES Reports Q1 Revenue $25.4M | MT |
| May. 07 | Transcript : SIGA Technologies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to SIGA Business Update Cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
Sector
Pharmaceuticals
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.59% | 530M | |
| +30.84% | 682B | |
| +30.35% | 586B | |
| -3.50% | 364B | |
| +18.13% | 327B | |
| +4.05% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.05% | 165B |
- Stock Market
- Equities
- SIGA Stock
- News SIGA Technologies, Inc.
- Transcript : SIGA Technologies, Inc., Q3 2021 Earnings Call, Nov 04, 2021